Journal of Radiotherapy / 2014 / Article / Tab 4 / Review Article
Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury Table 4 Evidence for the use of SABR in treating lung oligometastases.
Study Remarks Conclusions Okunieff et al. [56 ] Used SABR (5 Gy × 10 Fc) for both oligo- and multiple metastases. 50 patients with an overall 125 lesions. LC rate of 94%. Very low toxicity (2% risk of grade-3 toxicity). Improved median survival and PFS in comparison to contemporary standards of care. Joyner et al. [59 ] Utilized SABR (12 Gy × 3 Fc) to assess feasibility for centrally located lung metastases in 8 patients. All lesions confirmed locally controlled by PET/CT at median follow-up of 10.6 months. All lesions confirmed as locally controlled. Zhang et al. [60 ] Retrospective review of 71 patients treated with SABR (dose range of 30–60 Gy in 2–12 fractions). 1- and 5-year LC at 88.8% and 75.4%. No grade-3 toxicities. Rusthoven et al. [57 ] Assessed safety and efficacy of high-dose SABR (20 Gy × 3 Fc). Local control of 100% and 96%, at 1 and 2 years, respectively. Low incidence of toxicity (8% grade-3 and 0% grade-4). Norihisa et al. [58 ] Retrospective analysis. 34 patients of lung oligometastases treated with SABR with 12 Gy fractions (48 Gy in 18 patients and 60 Gy in 16 patients). 2 year OS of 84.3%, and LC of 90%. No incidence of local progression among the 16 patients treated with 60 Gy. SABR results comparable to surgical metastasectomy.
PET-CT: positron emission tomography—computed tomography; PFS: progression free survival; LC: local control; Fc: fraction.
